Shares of NewLink Genetics ( NLNK), a clinical-stage company focused on developing and commercializing immunotherapeutic products for the treatment of cancer, plunged in pre-market trading after a competitor exploring the same areas of cancer treatment reported a clinical trial that did not succeed in achieving its goal.
NewLink Genetics Plunges After Competitor IDO Drug Fails In Trial
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться